Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 24;9(3):e001458. doi: 10.1136/jitc-2020-001458

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Impact of DNA methylation on progression-free survival (PFS) and overall survival (OS) of patients with sarcoma treated with anti-programmed cell death 1 (anti-PD-1) immune checkpoint inhibitor (ICI). (A) Heatmap summarizing methylation of 2453 DMPs in 35 sarcoma samples. Patients’ characteristics including response to anti-PD-1 ICI, sarcoma subtype as well as expression of immune markers are displayed according to the color scheme shown at the right-hand side of the figure. Each row represents a unique CpG site and each column represents a unique patient sample. Heatmap colors reflect beta values representing the degree of methylation from low (blue) to high (red). No centering/scaling of beta values was performed. Immune markers were divided into first, second, third and fourth quarter. (B) PFS and OS (C) of patients with sarcoma from anti-PD-1 ICI therapy start in months. Blue and red lines indicate patients included in the methylation clusters MC1 and MC2, respectively. Vertical lines indicate censored patients at last follow-up. P values were calculated using log-rank tests.